Merus

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Merus and other ETFs, options, and stocks.

About MRUS

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors.

CEO

Sven Ante Lundberg

CEOSven Ante Lundberg

Employees

260

Employees260

Headquarters

Utrecht, Utrecht

HeadquartersUtrecht, Utrecht

Founded

2003

Founded2003

Employees

260

Employees260

MRUS Key Statistics

Market cap

7.21B

Market cap7.21B

Price-Earnings ratio

-17.77

Price-Earnings ratio-17.77

Dividend yield

—

Dividend yield—

Average volume

1.46M

Average volume1.46M

High today

$95.08

High today$95.08

Low today

$94.76

Low today$94.76

Open price

$94.78

Open price$94.78

Volume

591.43K

Volume591.43K

52 Week high

$95.30

52 Week high$95.30

52 Week low

$33.19

52 Week low$33.19

MRUS News

TipRanks 1d

Cautious Hold Rating on Merus Amid Genmab Acquisition Uncertainty and Promising Pipeline

William Blair analyst Matt Phipps has maintained their neutral stance on MRUS stock, giving a Hold rating on October 24. Elevate Your Investing Strategy: Take a...

TipRanks 3d

Merus NV’s Financial Stability at Risk Due to Unproven ADClonics Technology and Supply Chain Vulnerabilities

Merus NV (MRUS) has disclosed a new risk, in the Innovation / R&D category. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Un...

Analyst ratings

88%

of 17 ratings

Buy

11.8%

Hold

88.2%

Sell

People also own

Based on the portfolios of people who own MRUS. This list is generated using Robinhood data, and it’s not a recommendation.

Taiwan Semiconductor Manu…